🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for NSCLC Stage IV

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib combined with Docetaxel Pulmonary Rehabilitation in Advanced Lung Cancer Survivors NCT07104630Phase 21 site📍 Cleveland Case Comprehensive Cancer Center · Tests: Pulmonary Rehabilitation (PR), No intervention: Usual care A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) NCT05657873Phase 29 sites📍 Miami📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer NCT02133196Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer NCT06928389Phase 31 site📍 Shanghai Akeso · Tests: Ivonescimab, docetaxel, Placebo, docetaxel Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) NCT07154706Phase 333 sites📍 Los Angeles📍 Orange📍 Washington D.C. Nuvation Bio Inc. · Tests: Taletrectinib, Placebo A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764Phase 274 sites📍 Washington D.C.📍 Athens📍 Lexington Bristol-Myers Squibb · Tests: Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade NCT07130032Phase 21 site📍 Saint Petersburg EuroCityClinic LLC · Tests: reICB regimen (NSCLC), reICB regimen (melanoma) A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) NCT06731907Phase 241 sites📍 Lexington📍 Baltimore📍 Fargo Merck Sharp & Dohme LLC · Tests: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites📍 Sacramento📍 Tampa📍 Tampa National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 NCT04613596Phase 2, Phase 3770 sites📍 Goodyear📍 Prescott Valley📍 Safford Mirati Therapeutics Inc. · Tests: Adagrasib, Adagrasib, Adagrasib, Adagrasib, Pembrolizumab Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer NCT03199651NA1 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Best Practice, Biospecimen Collection, Biospecimen Collection, Laboratory Biomarker Analysis, Medical Chart Review A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07056556Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M09D1 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277Phase 3304 sites📍 La Mesa📍 Los Alamitos📍 Newark AstraZeneca · Tests: Rilvegostomig, Pembrolizumab Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer NCT07288632n/a1 site📍 Perugia University Of Perugia Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients NCT06114108NA7 sites📍 Aarau📍 Bellinzona📍 Chur Swiss Cancer Institute · Tests: Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy), Surgery, Radiotherapy Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer NCT07436858Phase 11 site📍 Amsterdam The Netherlands Cancer Institute · Tests: PET imaging with ⁸⁹Zr-trastuzumab, Blood sampling for pharmacokinetics Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) NCT07393555Phase 241 sites📍 Berkeley📍 Palo Alto📍 Sacramento SWOG Cancer Research Network · Tests: Biospecimen Collection, Computed Tomography, Ivonescimab, Magnetic Resonance Imaging, Sacituzumab Govitecan Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. NCT06167460n/a1 site📍 Ho Chi Minh City Gene Solutions A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation NCT07231068Phase 1, Phase 25 sites📍 Beijing📍 Beijing📍 Guangzhou Henan Genuine Biotech Co., Ltd. · Tests: Dositinib mesylate tablets A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer NCT07227025Phase 1, Phase 212 sites📍 New York📍 Fairfax📍 Toronto Janssen Research & Development, LLC · Tests: Amivantamab, Olomorasib Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer NCT07250477Phase 24 sites📍 Chico📍 Marysville📍 Sacramento University of California, Davis · Tests: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer NCT06512051Phase 1, Phase 21 site📍 Beijing Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injection, Carboplatin injection, Bevacizumab Injection Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib NCT04486833Phase 1, Phase 210 sites📍 Los Angeles📍 Lone Tree📍 Urbana Genprex, Inc. · Tests: quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites📍 Springdale📍 Duarte📍 Irvine AbbVie · Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597Phase 441 sites📍 Tucson📍 Hot Springs📍 Little Rock AstraZeneca · Tests: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) NCT07680790Phase 3204 sites📍 Beverly Hills📍 Fullerton📍 La Jolla Bristol-Myers Squibb · Tests: Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC NCT07467863Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive Care A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC NCT05543330Phase 1, Phase 21 site📍 Hangzhou Wuhan YZY Biopharma Co., Ltd. · Tests: M701 pleural infusion, Pleural drainage, Cisplatin pleural infusion
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy